Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26942237 | 0.83 | APOBEC3G (0.57) | APOBEC3GSLC6A4SLC6A2ALDH1A1 | |
| SCHEMBL14507031 | 0.82 | GABRA1 (0.41) | APOBEC3GHPGDALDH1A1HSD17B10ALOX15 | |
| SCHEMBL27460963 | 0.81 | APOBEC3G (0.50) | APOBEC3GSLC6A4HPGDSLC6A2CYP2D6 | |
| SCHEMBL9727526 | 0.80 | APOBEC3G (0.53) | APOBEC3GSLC6A4ALDH1A1LMNAHTT | |
| SCHEMBL9988198 | 0.80 | APOBEC3G (0.37) | APOBEC3GSLC6A4HPGDSLC6A2ALDH1A1 | |
| SCHEMBL3027067 | 0.78 | HPGD (0.36) | APOBEC3GHPGDALDH1A1HSD17B10ALOX15 | |
| SCHEMBL28252319 | 0.78 | HPGD (0.36) | APOBEC3GHPGDALDH1A1HSD17B10MITF | |
| SCHEMBL3842830 | 0.78 | SLC6A2 (0.46) | APOBEC3GSLC6A4HPGDSLC6A2ALDH1A1 | |
| SCHEMBL7674655 | 0.78 | HPGD (0.39) | APOBEC3GHPGDALDH1A1HSD17B10ALOX15 | |
| SCHEMBL9793625 | 0.78 | S100A4 (0.41) | HPGDALDH1A1HSD17B10ALOX15MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9635857-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013086451-A2 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-2580216-A2 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | Afraxis, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011159945-A2 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159945-A2 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011156780-A2 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011156780-A2 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| EP-1259506-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| US-6387911-B1 | Pyrazinone thrombin inhibitors | MERCK & CO., INC. | 2002-05-14 | — | — | US | disclosed |
| WO-2001038323-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK6 | APOBEC3G 4339/4885SLC6A4 1270/4885HPGD 3058/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | APOBEC3G 4042/4885SLC6A4 4557/4885HPGD 1889/4885 |
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | MRPS17, TAOK1, TAOK3 | APOBEC3G 3833/4885SLC6A4 4702/4885HPGD 4613/4885 |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | SMN1; SMN2, PYGB, PMP22 | APOBEC3G 2602/4885SLC6A4 1946/4885HPGD 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.